Bingnan Zhang

1.9k total citations
31 papers, 487 citations indexed

About

Bingnan Zhang is a scholar working on Molecular Biology, Oncology and Electrical and Electronic Engineering. According to data from OpenAlex, Bingnan Zhang has authored 31 papers receiving a total of 487 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 11 papers in Oncology and 7 papers in Electrical and Electronic Engineering. Recurrent topics in Bingnan Zhang's work include Lung Cancer Research Studies (6 papers), Cancer therapeutics and mechanisms (4 papers) and Cancer Genomics and Diagnostics (3 papers). Bingnan Zhang is often cited by papers focused on Lung Cancer Research Studies (6 papers), Cancer therapeutics and mechanisms (4 papers) and Cancer Genomics and Diagnostics (3 papers). Bingnan Zhang collaborates with scholars based in United States, China and Switzerland. Bingnan Zhang's co-authors include Anthony F. Porto, Elisa F Long, Richard S. Finn, Jingyu Sun, Jianhui Sun, Lauren A. Byers, Carl M. Gay, Tongzhang Zheng, Shelia Hoar Zahm and Theodore R. Holford and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Bingnan Zhang

30 papers receiving 473 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bingnan Zhang United States 12 164 130 72 66 64 31 487
Jing Fu China 17 168 1.0× 359 2.8× 185 2.6× 59 0.9× 82 1.3× 42 768
Han Liu China 14 92 0.6× 182 1.4× 93 1.3× 56 0.8× 39 0.6× 38 409
Xiao-Xin Zhang China 16 155 0.9× 319 2.5× 186 2.6× 94 1.4× 7 0.1× 36 667
Kang Lu China 17 159 1.0× 252 1.9× 65 0.9× 30 0.5× 12 0.2× 58 629
Chunxiao Zhang China 8 365 2.2× 337 2.6× 235 3.3× 112 1.7× 11 0.2× 12 808
Fumiya Ito Japan 14 70 0.4× 347 2.7× 158 2.2× 297 4.5× 7 0.1× 25 749
Jiahong Jiang China 15 159 1.0× 451 3.5× 372 5.2× 55 0.8× 28 0.4× 36 737
Junnan Guo China 14 103 0.6× 238 1.8× 161 2.2× 70 1.1× 3 0.0× 33 471
Guido Natoli Italy 10 201 1.2× 109 0.8× 111 1.5× 66 1.0× 11 0.2× 21 418
Bin Lai China 8 138 0.8× 104 0.8× 58 0.8× 87 1.3× 18 0.3× 21 376

Countries citing papers authored by Bingnan Zhang

Since Specialization
Citations

This map shows the geographic impact of Bingnan Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bingnan Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bingnan Zhang more than expected).

Fields of papers citing papers by Bingnan Zhang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bingnan Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bingnan Zhang. The network helps show where Bingnan Zhang may publish in the future.

Co-authorship network of co-authors of Bingnan Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of Bingnan Zhang. A scholar is included among the top collaborators of Bingnan Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bingnan Zhang. Bingnan Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rao, Qing, Hui Zhou, Wen-Kai Weng, et al.. (2025). Early detection, clinicopathological subtyping, and prognosis prediction for endometrial cancer patients using fragmentomics liquid biopsy assay. ESMO Open. 10(10). 105770–105770. 1 indexed citations
2.
Singhi, Eric K., Luisa M. Solis, Wei‐Lien Wang, et al.. (2025). Real-world efficacy and safety of tarlatamab in patients with relapsed extensive-stage small cell lung cancer.. Journal of Clinical Oncology. 43(16_suppl). 8088–8088. 1 indexed citations
3.
Zhang, Bingnan, et al.. (2023). Novel therapeutic strategies for recurrent SCLC. Critical Reviews in Oncology/Hematology. 186. 104017–104017. 6 indexed citations
4.
Zhang, Bingnan, Zhen Luo, Hao Yang, et al.. (2023). Induction of tetraploids in Paper Mulberry (Broussonetia papyrifera (L.) L’Hér. ex Vent.) by colchicine. BMC Plant Biology. 23(1). 574–574. 10 indexed citations
5.
Zhang, Bingnan, et al.. (2023). Recurrent Strokes in a Woman with a History of Thrombotic Thrombocytopenic Purpura. SHILAP Revista de lepidopterología. 2023. 1–3.
6.
Zhang, Bingnan, Yan Yang, C. Allison Stewart, et al.. (2023). Abstract 3196: Subtype-specific targeting of cell surfaceome with CAR T therapies in small cell lung cancer. Cancer Research. 83(7_Supplement). 3196–3196. 1 indexed citations
7.
Li, Bingyu, Bingnan Zhang, Yanan Zhang, et al.. (2021). Porous g-C3N4/TiO2 S-scheme heterojunction photocatalyst for visible-light driven H2-production and simultaneous wastewater purification. International Journal of Hydrogen Energy. 46(64). 32413–32424. 69 indexed citations
8.
Zhang, Bingnan, Kavya Ramkumar, Robert J. Cardnell, et al.. (2021). A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers. British Journal of Cancer. 125(10). 1333–1340. 37 indexed citations
9.
Kundu, Kiran, Robert J. Cardnell, Bingnan Zhang, et al.. (2021). SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer. Translational Lung Cancer Research. 10(11). 4095–4105. 29 indexed citations
10.
Zhang, Bingnan, C. Allison Stewart, Carl M. Gay, et al.. (2021). Abstract 384: Detection of DNA replication blocker SLFN11 in tumor tissue and circulating tumor cells to predict platinum response in small cell lung cancer. Cancer Research. 81(13_Supplement). 384–384. 6 indexed citations
11.
Zhang, Bingnan & Elisa F Long. (2019). Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer. Breast Cancer Research and Treatment. 175(3). 775–779. 37 indexed citations
12.
Zhang, Bingnan & Sara A. Hurvitz. (2016). Long-term outcomes of neoadjuvant treatment of HER2-positive breast cancer.. PubMed. 14(7). 520–30. 14 indexed citations
13.
Zhang, Bingnan & Richard S. Finn. (2016). Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection. Liver Cancer. 5(3). 221–232. 38 indexed citations
14.
Zhang, Bingnan, et al.. (2014). Tumor lysis syndrome and acute anemia in an African-American man with chronic lymphocytic leukemia. Oxford Medical Case Reports. 2014(8). 138–140. 6 indexed citations
15.
Zhang, Bingnan, Jean L. Bolognia, Peter Marks, & Nikolai A. Podoltsev. (2014). Enhanced skin toxicity associated with the combination of clofarabine plus cytarabine for the treatment of acute leukemia. Cancer Chemotherapy and Pharmacology. 74(2). 303–307. 12 indexed citations
16.
Zhang, Bingnan, et al.. (2014). Characterization of aggressive interventions within 30 days of death in lung cancer patients at Smilow Cancer Hospital (SCH).. Journal of Clinical Oncology. 32(30_suppl). 20–20. 3 indexed citations
17.
Podoltsev, Nikolai A., et al.. (2013). Chemoimmunotherapy and Withdrawal of Immunosupression for Monomorphic Posttransplant Lymphoproliferative Disorders. Clinical Lymphoma Myeloma & Leukemia. 13(6). 716–720. 3 indexed citations
18.
Li, Fang, et al.. (2011). Targeted therapy in breast cancer: what’s new?. Swiss Medical Weekly. 141(2526). w13231–w13231. 30 indexed citations
19.
Dai, Hong, et al.. (2006). 4-Fluoro-N-[4-(pyridin-4-yl)thiazol-2-yl]benzamide. Acta Crystallographica Section E Structure Reports Online. 62(11). o5330–o5331. 1 indexed citations
20.
Zheng, Tongzhang, Theodore R. Holford, John Tessari, et al.. (2000). Oxychlordane and trans-nonachlor in breast adipose tissue and risk of female breast cancer.. PubMed. 5(3). 153–60. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jing Fu Breakdown of academic impact, for papers by Han Liu Breakdown of academic impact, for papers by Xiao-Xin Zhang Breakdown of academic impact, for papers by Kang Lu Breakdown of academic impact, for papers by Chunxiao Zhang Breakdown of academic impact, for papers by Fumiya Ito Breakdown of academic impact, for papers by Jiahong Jiang Breakdown of academic impact, for papers by Junnan Guo Breakdown of academic impact, for papers by Guido Natoli Breakdown of academic impact, for papers by Bin Lai
Rankless by CCL
2026